Content continues after advertisement

Research Note: Oxyclozanide as Treatment for Small Animal Bacterial Pathogens

Sign in to Print/View PDF

Repurposing existing drugs and using a topical antimicrobial as a first-line treatment option for superficial pyoderma can help promote good antimicrobial stewardship, protect the efficacy of newer systemic antimicrobial classes, and limit use of newer antimicrobial classes. The aim of this study was to provide proof-of-concept for repurposing the drug oxyclozanide, a salicylanilide anthelmintic used primarily in humans and ruminants, as a topical treatment option for superficial pyoderma in small animals. Results showed promising in vitro activity against both methicillin-sensitive and methicillin-resistant Staphylococcus pseudintermedius canine isolates. Pilot data from this study may help guide clinical studies of topical application of oxyclozanide.


For global readers, a calculator to convert laboratory values, dosages, and other measurements to SI units can be found here.

All Clinician's Brief content is reviewed for accuracy at the time of publication. Previously published content may not reflect recent developments in research and practice.

Material from Clinician's Brief may not be reproduced, distributed, or used in whole or in part without prior permission of Educational Concepts, LLC. For questions or inquiries please contact us.


Clinician's Brief:
The Podcast
Listen as host Alyssa Watson, DVM, talks with the authors of your favorite Clinician’s Brief articles. Dig deeper and explore the conversations behind the content here.
Clinician's Brief provides relevant diagnostic and treatment information for small animal practitioners. It has been ranked the #1 most essential publication by small animal veterinarians for 9 years.*

*2007-2017 PERQ and Essential Media Studies

© 2022 Educational Concepts, L.L.C. dba Brief Media ™ All Rights Reserved. Terms & Conditions | DMCA Copyright | Privacy Policy | Acceptable Use Policy